Brazil is the low-prevalence, medical-only case: circumcision is rare (~7%), the intact penis is the norm, there's no religious/cultural tradition, and where it happens it's therapeutic (phimosis etc.). The public system (SUS) funds it ONLY for medical indications — 668,818 procedures over 1984–2010 (Korkes 2012); a 2011 bill (PL 790, archived) framed it as phimosis therapy. No statute restricts it.
The distinctive angle: Brazil has a world-famous HIV response — universal ART, PrEP (free in SUS since 2018), condoms, harm reduction — and it does NOT use circumcision. WHO scopes VMMC to 15 generalized-epidemic countries in East/Southern Africa; Brazil's concentrated epidemic isn't among them. It's the clearest "studied circumcision-for-HIV and chose a different path" case.
Honest caveats: TWO prevalence estimates with different scope (~7% small sample vs ~1.3% SUS-medical — don't merge); the 63 SUS deaths (1992–2010, 0.013%) are "associated with" admissions, elderly-concentrated, NONE in infants — not botched-baby cases; the Curitiba 3.27% is a reoperation rate; VMMC absence framed via WHO scoping, not a verbatim protocol claim.
Switch to the in-depth article for the full picture and sources (#231–238).
Brazil is a country where circumcision barely registers as a cultural question at all. The intact penis is the norm; only around 7% of Brazilian men are circumcised, and where it happens it is almost always for a medical reason — a tight foreskin, an infection — not religion or ritual. What makes Brazil worth its own file is not the practice but the policy: this is a country with one of the world's most admired HIV responses, which looked at circumcision as a prevention tool and built its strategy on everything except it.
The sources here are numbered references (#231–238) in the references library and against the Brazil country profile. Two things are stated with care below: the prevalence number (two estimates with different scope) and the harm data (real, but clinical and elderly-concentrated, not botched-infant cases).
Rare, and almost entirely medical
Brazil has no continuing religious or cultural mass-circumcision tradition — pre-Columbian practice largely vanished after the European conquest, and the country's small Jewish and Muslim minorities aside, circumcision simply is not a Brazilian custom. The figures reflect that, with an important nuance worth keeping straight. The most-cited prevalence is ~7% (UNAIDS, drawn from a small 2005 study of male partners in a cervical-cancer cohort — one estimate, not a census). Separately, Brazil's public health system recorded that only about 1.3% of the male population needed a medically-indicated circumcision over 1984–2010 — a public-system, medical-only figure, not overall prevalence. Both point the same way: uncommon, and overwhelmingly therapeutic. The leading reasons are phimosis, paraphimosis, recurrent balanoposthitis and the like, with circumcisions peaking in childhood and rising again after age 60.
The public system pays — but only for medicine
Brazil's universal health system, the SUS, funds and performs circumcision — but strictly for medical indications, never ritually or prophylactically. Over 1984–2010 it carried out 668,818 such procedures (a steady ~48 per 100,000 men per year; Korkes et al., 2012). The legislative lens matches: a 2011 bill, PL 790/2011, proposed obligating the SUS to screen young children for phimosis and provide corrective surgery when needed — framing circumcision as therapy. (It was archived in 2019 without becoming law.) There is no Brazilian statute restricting non-therapeutic circumcision of minors, and none mandating it either; the practice is simply treated as a medical question.
The country that studied circumcision and said no
Here is what sets Brazil apart. It has a serious HIV epidemic — low overall prevalence (around 0.4% in the general population, ~0.6–0.7% among adults 15–49), nationally stable, and concentrated in key populations — and a globally celebrated response to it. That response is built on universal antiretroviral treatment, PrEP (available free in the SUS since 2018), condoms and harm reduction. It is not built on circumcision. This is not an oversight: the WHO's voluntary medical male circumcision (VMMC) recommendation applies specifically to the 15 priority countries in East and Southern Africa with generalized epidemics, where the supporting trials were run. Brazil's epidemic is concentrated, not generalized, and Brazil is not on that list. So while VMMC was scaled to tens of millions of men in Africa, Brazil — facing its own epidemic — reached for treatment-as-prevention and PrEP instead. Brazil is the clearest example in this index of a country that weighed circumcision as public health and chose a different path.
When it goes wrong
Because circumcision in Brazil is a medical procedure, its documented harms are clinical — and worth framing precisely. A pediatric centre in Curitiba reported a 3.27% reoperation rate (80 of 2,441 boys in a single year) for complications such as paraphimosis, bleeding and preputial stenosis — that is the rate of complications serious enough to need a second operation, not the total complication rate. And the national SUS data recorded 63 deaths "associated with" circumcision admissions over 1992–2010 (0.013%). That figure needs its caveats stated plainly: the database does not record cause of death, the deaths were "associated with" (occurred during) the admission rather than confirmed to be caused by the procedure, and they were concentrated in elderly men with comorbidities — with none in infants. This is not a record of botched baby circumcisions; it is the surgical-risk profile of an operation done largely on older, sicker patients.
The honest bottom line
Brazil shows circumcision stripped of culture and religion: a rare, medical, publicly-funded-when-indicated procedure in a country where the foreskin is simply left in place. Its real lesson is on the policy side — for a bodily-autonomy lens, Brazil is the proof that a country can take HIV deadly seriously and still decline to circumcise its way out of it, choosing treatment and prevention tools that don't involve surgery on healthy bodies.
Compiled from a June 2026 deep-research pass: prevalence (UNAIDS JC1360 from Castellsague et al., Am J Epidemiol 2005; Morris et al. 2016); the SUS medical epidemiology (Korkes et al., Einstein 2012); the HIV strategy (Brazilian MoH STI Protocol 2020) and WHO VMMC scoping; the legislative framing (PL 790/2011, archived); and clinical harm (Talini et al., Einstein 2018; Korkes 2012). Prevalence is given as two estimates with their scope. The 63 SUS deaths are "associated with" admissions, elderly-concentrated, none in infants — not botched-infant cases; the 3.27% is a reoperation rate. VMMC's absence is framed via WHO scoping. See references #231–238.
